U.S. Peripheral Vascular Angiography Contrast Media Market Size to Hit Around USD 429.5 Million by 2034

The U.S. peripheral vascular angiography contrast media market size was exhibited at USD 233.15 million in 2024 and is projected to hit around USD 429.5 million by 2034, growing at a CAGR of 6.3% during the forecast period 2025 to 2034.

U.S. Peripheral Vascular Angiography Contrast Media Market Key Takeaways:

• The CT/X-ray segment dominated the market in 2024 and is expected to register a significant CAGR from 2025 to 2034.
• The hospital end use segment dominated the market share of 40.0% in 2024.
• The diagnostic imaging centers segment is anticipated to grow significantly over the forecast period.

?????????????? ?????? ???????? ???????????? ????????????: https://www.novaoneadvisor.com/report/sample/9050

The rising prevalence of Peripheral Vascular Diseases (PVDs) in the U.S. is a significant driver of the peripheral vascular imaging contrast media market. Increased need for advanced diagnostic and therapeutic tools to manage these conditions effectively. According to the Heart Disease and Stroke Statistics by the American Heart Association 2023, prevalence of Peripheral Artery Disease (PAD) estimates indicate 7 to 12 million affected individuals in the U.S.

The growing burden of peripheral artery disease is anticipated to boost the U.S. peripheral vascular angiography contrast media industry growth over the forecast period. Peripheral vascular angiography is conducted to diagnose peripheral artery disease. According to an article published by the Trustees of the University of Pennsylvania in June 2024, an estimated 21 million Americans already live with peripheral artery disease (PAD), and this number is anticipated to grow to 24 million by 2034.

The growing prevalence of the aging population in countries such as the U.S. and Japan is expected to drive market growth. Older individuals are more prone to developing peripheral vascular or peripheral artery diseases. According to data from the Population Reference Bureau published in January 2024, the number of people aged 65 and older in the U.S. is projected to increase by 47%, from 58 million in 2022 to 82 million by 2050. The proportion of the population aged 65 and above is anticipated to rise from 17% to 23%. Aging is a significant risk factor for vascular and chronic diseases. As the geriatric population grows, there will be an increased prevalence of chronic conditions such as cardiovascular diseases and other lifestyle-related disorders, further elevating the risk of peripheral artery diseases.

The increasing prevalence of lifestyle-related disorders, such as diabetes, obesity, smoking, and hypertension, is a major driver of the peripheral vascular angiography contrast media market. These conditions are strongly associated with a higher risk of vascular diseases, including peripheral artery disease, atherosclerosis, and other circulatory disorders. As the global incidence of these conditions rises, the demand for diagnostic imaging procedures, including angiography with contrast media, has also grown. Peripheral vascular angiography procedures, which rely on contrast agents to produce clear and precise images of blood vessels, play a critical role in the early diagnosis of these conditions, enabling timely interventions that can enhance patient outcomes.

U.S. Peripheral Vascular Angiography Contrast Media Market By Product Insights

The CT/X-ray segment dominated the market in 2024 and is expected to register a significant CAGR from 2025 to 2034. CT angiography is a medical imaging technique that combines a CT scan with injecting a special dye called contrast material. This dye helps to visualize blood vessels and tissues better during the scan. A CT scan is an X-ray that uses a computer to generate cross-sectional images of the body. The contrast material is crucial for CT angiography as it enhances the visibility of the examined structures. CT angiography utilizes minimal radiation, minimizing the associated risks. While there's always a slight theoretical risk with any radiation exposure, the benefits of accurate diagnosis typically outweigh these minimal concerns. Importantly, no radiation remains within the body after a CT scan. The rising prevalence of Congenital Heart Diseases (CHDs) significantly increases the demand for CT angiography. Accurate diagnosis and effective management of CHDs necessitate precise imaging techniques, and CT angiography has emerged as an invaluable tool in this context. For instance, as per a report by the CDC, in October 2024, in the U.S., nearly 1% of babies are born with heart defects, amounting to an estimated 40,000 newborns annually.

U.S. Peripheral Vascular Angiography Contrast Media Market By Modality Insights

Iodinated contrast media dominated the peripheral vascular angiography contrast media market due to their high efficacy in enhancing the visibility of blood vessels in imaging modalities such as X-ray, CT, and angiography. These agents improve the contrast and clarity of vascular structures, enabling accurate diagnosis and treatment planning. Their well-established safety profile and consistent and predictable results have made them a trusted choice among healthcare professionals. In addition, iodinated contrast media are versatile, compatible with various imaging techniques, and offer fast action with predictable outcomes, making them ideal for emergency and routine diagnostic scenarios. With a strong market presence from leading companies like Bayer and GE HealthCare, iodinated contrast agents dominate the market, driven by their proven effectiveness and wide usage.

U.S. Peripheral Vascular Angiography Contrast Media Market By End Use Insights

The hospital end use segment dominated the market share of 40.0% in 2024. The hospital segment of the peripheral vascular angiography contrast media market is a key driver of growth, as hospitals are the primary healthcare setting for performing vascular imaging procedures. These procedures, which use contrast media to visualize blood vessels and diagnose vascular diseases, are crucial in treating conditions such as peripheral artery disease (PAD) and other vascular abnormalities. In this segment, the demand for PVA contrast media is influenced by factors such as increasing patient volumes, advancements in imaging technology, and the rising prevalence of vascular diseases.

The diagnostic imaging centers segment is anticipated to grow significantly over the forecast period, driven by rising demand for advanced diagnostic services and non-invasive imaging technologies. These centers, which specialize in procedures such as angiography, are adopting PVA contrast media due to their effectiveness in improving the visualization of blood vessels. This enhancement is crucial for diagnosing vascular conditions such as peripheral artery disease and vascular blockages, further fueling the market expansion in this segment.

Some of the prominent players in the U.S. peripheral vascular angiography contrast media market include:

• Guerbet
• Bracco
• Bayer
• GE HealthCare
• Fresenius Kabi USA
• Lantheus Holdings, Inc.

U.S. Peripheral Vascular Angiography Contrast Media Market Recent Developments

• In December 2024, at the 2024 Radiological Society of North America annual meeting, Bayer showcased advancements in its radiology portfolio, highlighting progress in AI, medical imaging, and contrast agents. Bayer presented Phase III data on its investigational low-dose macrocyclic gadolinium-based contrast agent, which enables reduced dosing while maintaining diagnostic efficacy. The research, honored with the Kuo York Chynn Neuroradiology Research Award, focuses on its pharmacokinetics, dose selection, and imaging potential for CNS lesions and MR angiography.
• In October 2024, GE HealthCare announced the successful completion of its Phase I clinical trial for a macrocyclic manganese-based MRI contrast agent. The study demonstrated that the agent was well tolerated, with no serious adverse events, dose-limiting toxicities, or clinically relevant findings reported.
• In July 2024, Bracco and Verasonics, Inc. announced a strategic partnership aimed at enhancing research in medical imaging. This collaboration will merge Verasonics' Vantage NXT Research Ultrasound Systems with Bracco's contrast agents to investigate enhanced imaging performance across a range of research applications. The agreement also entails joint marketing initiatives, including online content and webinars, to present the outcomes of their research efforts.
• In April 2024, the Bracco Group announced that it will launch its direct autonomous presence in the Japanese market starting April 2024. The newly formed Bracco Japan will gradually replace Bracco Eisai, the joint venture that was established in 1990 and renewed twice.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the U.S. peripheral vascular angiography contrast media market

By Product

• CT/X-ray
• Magnetic Resonance Imaging
• Ultrasound

By Modality

• Iodinated Contrast Media
• Gadolinium-based Contrast Media
• Microbubble

By End Use

• Hospitals
• Diagnostic Imaging Centers
• Research Institutes
• Others

Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/9050

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

You can place an order or ask any questions, please feel free to [email protected]| +1 9197 992 333

About US

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Connect with Us

Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

IND Address: 707, Nandan Probiz, Baner,?Pune (MH) – 411045, India

USA:?+1 804 441 9344

APAC:?+61 485 981 310 or +91 87933 22019

Europe:?+44 7383 092 044

Email: [email protected]

Web: https://www.novaoneadvisor.com/

You can place an order or ask any questions, please feel free to contact at?[email protected] ?| +1 804 441 9344

Nova One Advisor Group Offer Other Reports:

DNA Methylation Market- https://www.biospace.com/press-releases/dna-methylation-market-size-to-hit-usd-6-26-billion-by-2034

Breast Cancer Liquid Biopsy Market -https://www.biospace.com/press-releases/breast-cancer-liquid-biopsy-market-size-to-hit-usd-2-89-billion-by-2034

U.S. Biopharmaceutical Third-party Logistics Market- https://www.biospace.com/press-releases/u-s-biopharmaceutical-third-party-logistics-market-size-to-surpass-usd-99-75-bn-by-203

Pediatric Clinical Trials Market- https://www.biospace.com/press-releases/pediatric-clinical-trials-market-size-to-hit-usd-27-65-billion-by-2033

DNA & Gene Chip Market- https://www.biospace.com/press-releases/dna-gene-chip-market-size-to-hit-around-usd-30-72-billion-by-2033

U.S. Exosomes Market- https://www.biospace.com/press-releases/u-s-exosomes-market-size-to-hit-usd-1-815-46-million-by-2033

Healthcare Patent Filing Outsourcing Market ?https://www.biospace.com/press-releases/healthcare-patent-filing-outsourcing-market-size-to-hit-usd-2-54-bn-by-2034

High Potency API Contract Manufacturing Market https://www.biospace.com/press-releases/high-potency-api-contract-manufacturing-market-size-to-hit-usd-23-00-bn-by-2034

Europe Clinical Trials Market -https://www.biospace.com/press-releases/europe-clinical-trials-market-size-to-hit-usd-43-billion-by-2034

Cell Culture Vessels Market- https://www.biospace.com/press-releases/cell-culture-vessels-market-size-to-surpass-usd-19-65-billion-by-2033

Radiology Information Systems Market https://www.biospace.com/press-releases/radiology-information-systems-market-size-to-hit-usd-3-92-billion-by-2034

In Vitro Diagnostics ( IVD ) Market https://www.biospace.com/press-releases/in-vitro-diagnostics-ivd-market-size-to-surpass-usd-157-56-billion-by-2034

Biological Skin Substitutes Market https://www.biospace.com/press-releases/biological-skin-substitutes-market-size-to-hit-usd-810-50-million-by-2034

Personalized Medicine Biomarkers Market https://www.biospace.com/press-releases/personalized-medicine-biomarkers-market-size-to-hit-usd-79-26-bn-by-2034

Omics-based Clinical Trials Market https://www.biospace.com/press-releases/omics-based-clinical-trials-market-size-to-hit-usd-70-92-billion-by-2034

Radiation Oncology Market https://www.biospace.com/press-releases/radiation-oncology-market-size-share-trends-analysis-report-by-2033

Life Science Tools Market https://www.biospace.com/press-releases/life-science-tools-market-size-share-trends-analysis-report-by-2033

Oncology Clinical Trials Market https://www.biospace.com/press-releases/oncology-clinical-trials-market-size-expected-to-reach-usd-22-11-bn-by-2033

Manufacturing Execution System in Life Sciences Markethttps://www.biospace.com/press-releases/manufacturing-execution-system-in-life-sciences-market-size-to-hit-usd-9-52-bn-by-2034